S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:REPH - Recro Pharma Stock Price, Forecast & News

$14.81
-0.53 (-3.46 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$14.61
Now: $14.81
$15.33
50-Day Range
$15.34
MA: $16.82
$18.78
52-Week Range
$5.53
Now: $14.81
$19.21
Volume279,800 shs
Average Volume274,336 shs
Market Capitalization$336.63 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.31
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.35 million
Book Value($0.91) per share

Profitability

Net Income$-79,720,000.00

Miscellaneous

Employees255
Market Cap$336.63 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.


Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) issued its earnings results on Friday, November, 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The specialty pharmaceutical company had revenue of $25.26 million for the quarter, compared to the consensus estimate of $19.83 million. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Recro Pharma.

What price target have analysts set for REPH?

3 brokerages have issued 12-month price objectives for Recro Pharma's shares. Their forecasts range from $7.50 to $20.00. On average, they anticipate Recro Pharma's stock price to reach $15.50 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

News stories about REPH stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Recro Pharma earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Recro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a decline in short interest in February. As of February 14th, there was short interest totalling 887,600 shares, a decline of 18.6% from the January 30th total of 1,090,000 shares. Based on an average daily volume of 327,700 shares, the short-interest ratio is currently 2.7 days. Currently, 4.6% of the shares of the stock are sold short. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.48%), Broadfin Capital LLC (3.17%), Panagora Asset Management Inc. (2.10%), State Street Corp (1.79%), Geode Capital Management LLC (1.26%) and Prudential Financial Inc. (1.26%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood and Healthcare Master Fun Broadfin. View Institutional Ownership Trends for Recro Pharma.

Which major investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Oxford Asset Management LLP, Essex Investment Management Co. LLC, Monarch Partners Asset Management LLC, Penn Capital Management Co. Inc., Walthausen & Co. LLC, Goldman Sachs Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Recro Pharma.

Which major investors are buying Recro Pharma stock?

REPH stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Calamos Advisors LLC, Renaissance Technologies LLC, EAM Global Investors LLC, Prudential Financial Inc., EAM Investors LLC, Russell Investments Group Ltd. and Panagora Asset Management Inc.. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $14.81.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $336.63 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.View Additional Information About Recro Pharma.

What is Recro Pharma's official website?

The official website for Recro Pharma is http://www.recropharma.com/.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel